quote:Nasdaq Panel Grants Corcept Therapeutics' Request for Listing on the Nasdaq Capital Market Wednesday April 4, 8:32 pm ET
MENLO PARK, CA--(MARKET WIRE)--Apr 4, 2007 -- Corcept Therapeutics Incorporated (NasdaqGM:CORT - News) announced today that a Nasdaq Listing Qualifications Panel has granted the company's request to be listed on the Nasdaq Capital Market, effective with the market opening on Monday, April 9, 2007. By transferring from the Nasdaq Global Market to the Nasdaq Capital Market, Corcept satisfies all listing requirements. The Company's trading symbol will remain CORT.
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases. Corcept's lead product, CORLUX®, is currently in Phase III clinical trials for the treatment of the psychotic features of PMD. The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to mitigate the effects of the elevated and abnormal release patterns of cortisol seen in PMD. The Company is also conducting a proof-of-concept study evaluating the ability of CORLUX to mitigate weight gain associated with the use of olanzapine. For additional information about the company, please visit www.corcept.com.
Statements made in this news release, other than statements of historical fact, are forward-looking statements. Forward-looking statements are subject to a number of known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied by such statements. Examples of such forward-looking statements include statements regarding the pending listing of Corcept common stock on the NASDAQ Capital Market. These and other risk factors are set forth in the Company's SEC filings, all of which are available from our website (www.corcept.com) or from the SEC's website (www.sec.gov). We disclaim any intention or duty to update any forward-looking statement made in this news release.
Contact: CONTACT: Joseph K. Belanoff, M.D. Chief Executive Officer Corcept Therapeutics 650-327-3270 Email Contact http://www.corcept.com
slightly more than 15%
Posted by stocktrader22 on :
Great Call Tex....bring these small cappers to the hot board...im telling you this section gets no play
Posted by EnergymanNJ on :
CORT..Should be spiking on new of market move to NASDAQ Capital.$$$$ IMO close 4.85
Posted by Jo4321 on :
It's looking good, Tex.
I am on a self-imposed buying moratorium this week, but I was tempted...
Jo
Posted by T e x on :
good today, lol...
haven't even charted this, yet... may be good...dunno
Posted by T e x on :
quote:Originally posted by stocktrader22: Great Call Tex....bring these small cappers to the hot board...im telling you this section gets no play
I hear ya, I do...
but some peeps have expressed interest in seeing more NAZ plays posted here...
Posted by T e x on :
btw, just ran it through my favorite chart guy--his take? If it closes above 1.60 without falling back to 1.30, forget the gaps needing to be filled...
just fwiw...
Posted by Free Muney on :
I jumped in on this one today. may be a little late. I set a trailing stop at 12%. I think the recent attention should carry green through the week at least.
Posted by Free Muney on :
doh stopped out in a hurry. Posted by Free Muney on :
![[Frown]](frown.gif)